Mindset announces new insights in research on psychedelics molecules via its COPE initiative.
Mindset announces new insights in research on psychedelics molecules via its COPE initiative.
Novamind announces a "clinical pilot" aimed at bringing ketamine-assisted therapy to treat the mental health disorders of frontline healthcare workers.
There are many valid reasons to push forward with legal reforms to advance psychedelic medicine. In the U.S., however, it is the treatment of PTSD that is bringing Republicans and Democrats together.
Cybin announces its Q3 results, supported by a conference call. Cash as of Decemeber 31, 2021 of CAD$63.6 million.
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol "PSYK".
Optimi Health announces receiving its Dealer's License from Health Canada, allowing the possession, production and sale of psilocybin.
Cheap stocks. Many reasons to invest. We selected five different companies who illustrated these value propositions.
Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now